CTSO CTSO

Q: What is the current share price of CTSO?

As of 2026-08-05 17:25 PDT, CTSO trades at $0.38 on NASDAQ/NYSE. Its 52-week range is $0.35 to $1.20.

Q: What is the P/E ratio of CTSO?

CTSO trades at a trailing price-to-earnings (P/E) ratio of -2.92.

Q: What is the return on equity (ROE) of CTSO?

CTSO has a return on equity (ROE) of -138.88%. Its return on capital employed (ROCE) is -41.30%.

Q: Is CTSO a good stock to buy?

This page provides a data-driven analysis of CTSO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Company Profile ↓

$0.38

-57.77% 1Y

P/E-2.92

52W High$1.20

52W Low$0.35

EPS (TTM)$-0.13

Company Overview

CTSO (CTSO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 70.5% CAGR over the past five years.

Recent Developments

Dec 2025 Revenue of $37.06M (+4.1% YoY); net profit $-8.20M.
Trailing 12 Months Year-on-year growth — revenue +4.1%.
5-Year Trend Long-term compounding — revenue CAGR 70.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	70.48%
1 Year:	4.12%

Stock Price Performance

1 Year:	-57.77%
6 Months:	-43.84%
3 Months:	-36.41%
1 Month:	-5.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 4% of range

$0.35 $1.20

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)49.80 · Neutral

Price Performance

1M-5.48%

3M-36.41%

6M-43.84%

1Y-57.77%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 70.5% over 5 years.

CONS

Trading 67.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-2.92

Industry PE

Forward P/E

PEG Ratio

Book Value

Price to Book

P/S

EV/EBITDA

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

70.48%

Profit 5Y

Revenue (YoY)

4.12%

Earnings (YoY)

Profitability & Returns

ROCE

-41.30%

ROE

-138.88%

ROA

-18.56%

Profit Margin

-22.12%

Op Margin

-38.42%

Gross Margin

71.48%

EPS (Latest Qtr)

$-0.08

EPS (TTM)

$-0.13

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

Current Ratio

Debt

Total Assets

$40.56M

Current Assets

Working Capital

Ownership

Promoter Holding

15.72%

Chg in Prom Hold

FII / Inst Holding

25.60%

Chg in FII Hold

Financial Snapshot

Enterprise Value

Total Revenue (TTM)

$37.06M

EBITDA

$-4.36M

Free Cash Flow

$-12.54M

Operating Cash Flow

$-12.38M

Shares Outstanding

Gross Margin

71.48%

Payout Ratio

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	1.81M	2.22M	2.41M	3.08M	3.11M	3.57M	3.82M	4.65M	4.92M	5.76M	5.74M	6.08M	5.19M	6.23M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	957.17K	990.68K	1.35M	1.45M	1.79M	1.86M	2.08M	2.31M	3.38M	3.36M	3.97M	3.69M	4.00M	3.45M	4.40M	4.40M	5.34M	6.32M	6.55M	7.66M	9.43M	7.85M	9.31M	7.30M	7.66M	6.41M	4.94M	3.62M	5.76M	5.46M	6.02M	5.61M	5.31M	6.87M	6.50M	5.26M	6.21M	6.81M	6.67M	6.13M
Operating Income	-2.21M	-2.09M	-2.69M	-2.14M	-4.57M	-1.56M	-2.33M	-2.15M	-3.81M	-3.10M	-4.19M	-2.71M	-5.59M	-4.29M	-3.63M	-5.63M	-5.43M	-2.48M	-3.30M	-1.96M	-2.63M	-2.85M	-4.92M	-5.41M	-9.56M	-7.79M	-8.36M	-9.02M	-6.36M	-7.89M	-6.56M	-7.35M	-9.41M	-4.66M	-3.57M	-4.83M	-3.89M	-3.62M	-2.86M	-3.04M
Net Income	-	-1.84M	-3.01M	-2.19M	-	-1.52M	-1.73M	-2.05M	-	-2.98M	-5.82M	-3.00M	-	-4.88M	-3.55M	-6.89M	-	-3.45M	-2.87M	-839.73K	-	-4.17M	-4.68M	-6.41M	-	-8.97M	-10.88M	-12.20M	-	-7.33M	-6.15M	-9.19M	-	-6.09M	-4.29M	-2.77M	-1.48M	1.95M	-3.17M	-5.13M
Diluted EPS	-0.08	-	-0.12	-	-	-	-	-	-	-	-	-	-	-0.15	-0.11	-0.21	-0.13	-0.10	-0.08	-0.02	0.00	-0.10	-0.11	-0.15	-0.25	-0.21	-0.25	-0.28	-0.02	-0.17	-0.15	-0.21	-0.12	-0.11	-0.08	-0.05	-0.02	0.03	-0.05	-0.08
R&D Expense	-	856.12K	1.09M	1.17M	-	469.55K	458.03K	643.19K	-	1.73M	1.58M	1.94M	-	2.42M	2.93M	3.19M	-	1.97M	2.41M	1.75M	-	2.28M	3.70M	4.26M	-	4.24M	4.18M	3.29M	-	4.21M	3.67M	3.75M	-	2.25M	1.52M	1.85M	1.66M	-	-	1.02M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36.08K	1.34M	2.42M	4.12M	4.79M	9.53M	15.15M	22.50M	24.95M	41.00M	-	29.36M	31.08M	35.59M	37.06M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.96M	9.13M	10.71M	10.57M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.32K	1.02M	511.10K	1.99M	2.58M	5.57M	9.63M	15.01M	17.59M	29.95M	-	15.40M	21.95M	24.89M	26.49M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46.93M	53.90M	41.34M	40.73M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.82M	-4.44M	-3.49M	-4.71M	-6.89M	-9.30M	-11.49M	-9.84M	-15.58M	-18.97M	-10.37M	-	-31.52M	-31.95M	-16.45M	-14.24M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30.39M	-27.88M	-19.27M	-4.36M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	157.89K	1.40M	2.61M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-33.91M	-30.06M	-22.41M	-8.60M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.09M	-813.74K	-1.69M	-401.00K
Net Income	-5.26M	-1.87M	-10.75M	-3.07M	-15.39M	-11.87M	-6.01M	-1.10M	-3.67M	-76.72M	-3.35M	-3.02M	-2.74M	-2.91M	-5.48M	-3.66M	-4.68M	-9.32M	-9.48M	-11.76M	-8.46M	-17.21M	-19.27M	-7.84M	-	-32.81M	-29.25M	-20.72M	-8.20M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.60	-0.20	-	-0.75	-0.65	-0.38	-0.13
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	1.76M	2.89M	2.53M	1.74M	2.43M	3.87M	4.07M	3.22M	7.72M	12.09M	8.81M	16.38M	15.12M	15.73M	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	1.81M	2.12M	3.34M	4.05M	8.47M	11.25M	9.69M	24.10M	34.20M	27.38M	89.95M	89.52M	63.23M	57.46M	52.44M	47.58M	52.96M	47.07M	53.43M	47.80M	47.37M	44.18M
Total Equity	877.48K	1.58M	100.55K	5.34M	2.33M	-4.37M	-3.91M	-6.97M	-9.76M	2.36M	-104.30K	-3.35M	-5.74M	-8.07M	-10.09M	-11.63M	-14.27M	6.94M	9.85M	1.34M	10.26M	16.93M	3.42M	79.22M	62.58M	35.37M	29.94M	24.46M	18.81M	23.48M	19.63M	17.43M	13.14M	11.11M	5.90M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	1.60M	1.06M	1.19M	1.73M	2.18M	3.61M	5.32M	5.25M	17.32M	22.37M	12.23M	71.42M	52.14M	22.14M	-	-	-	14.13M	-	-	-	3.28M	6.25M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	4.08M	5.99M	9.27M	13.39M	0	-	5.00M	-	-	-	2.54M	-	-	-	14.00M	16.67M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	2.30M	1.80M	2.08M	3.06M	-	3.04M	8.36M	13.84M	17.26M	23.96M	10.73M	26.94M	27.86M	27.52M	27.98M	28.76M	29.48M	27.44M	36.00M	34.66M	36.27M	38.28M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	1.22M	1.53M	2.08M	3.06M	4.51M	3.04M	4.28M	7.85M	6.92M	9.94M	10.15M	13.69M	9.71M	9.45M	9.99M	11.67M	14.04M	12.72M	9.64M	8.28M	9.82M	9.71M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-2.48M	-3.83M	-3.62M	-3.49M	-6.66M	-9.05M	-6.73M	-6.46M	-10.84M	-16.76M	-5.61M	-14.01M	-28.23M	-21.66M	-14.43M	-12.38M
Investing Cash Flow	-165.45K	-52.49K	-38.81K	-216.36K	-2.31M	-890.90K	1.60M	-1.68M	-1.52M	-1.52M	-1.68M	-4.28M	-6.46M	-936.24K	-669.00K	-415.00K
Financing Cash Flow	2.10M	4.01M	4.21M	4.20M	10.02M	11.64M	5.06M	20.12M	17.47M	8.18M	66.35M	715.20K	4.96M	14.47M	9.33M	9.31M
Capital Expenditure	-139.36K	-34.67K	-19.85K	-38.68K	-153.16K	-403.61K	-140.72K	-990.67K	-671.97K	-698.16K	-708.39K	-3.64M	-6.09M	-538.12K	-284.00K	-164.00K
Free Cash Flow	-2.62M	-3.86M	-3.64M	-3.53M	-6.81M	-9.45M	-6.87M	-7.45M	-11.51M	-17.46M	-6.32M	-17.65M	-34.32M	-22.19M	-14.71M	-12.54M

Ratios (Annual)

Figures in %.

Metric	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67.4%	76.2%	21.1%	48.2%	53.8%	58.5%	63.6%	66.7%	70.5%	73.0%	-	52.5%	70.6%	69.9%	71.5%
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,297.7%	-259.9%	-194.5%	-167.2%	-194.2%	-120.6%	-65.0%	-69.3%	-76.0%	-25.3%	-	-107.4%	-102.8%	-46.2%	-38.4%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,193.9%	-272.8%	-193.1%	-226.1%	-197.8%	-123.5%	-55.8%	-76.5%	-77.2%	-19.1%	-	-111.8%	-94.1%	-58.2%	-22.1%
ROE %	-599.0%	-118.2%	-10,695.3%	-57.4%	-660.9%	271.4%	153.8%	15.7%	37.6%	-3,246.5%	3,212.7%	90.2%	47.7%	36.1%	54.3%	31.5%	32.8%	-134.2%	-96.2%	-879.5%	-82.4%	-101.6%	-563.6%	-9.9%	-	-92.8%	-124.6%	-186.5%	-138.9%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	-476.4%	-746.2%	-276.5%	-480.5%	-173.9%	-113.3%	-212.2%	-60.6%	-57.1%	-108.8%	-13.0%	-	-58.9%	-82.1%	-43.8%	-41.3%

Shareholding Pattern

Insiders

15.72%

Institutions

25.60%

Public Float

30.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CTSO

Google News Wed, 13 May 2026

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PR Newswire

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxPYzRvS014bC04bUxUc0xvYVNMYTJrWGhXUlhvYW92VklUcHpHalF0akc3allMZmxPWFRSNE02OWRlQmZCOHQ5ei1UY2xMSFdaMUROMHZyUVozQWdSVjd3TU52QTgtQVpLOUJXUFoxNTJwbDBvV1c3cTFJcGJKY2xoTi13VU1MNmFFTzc4Qk…

Google News Mon, 20 Jul 2026

CytoSorbents to discuss blood purification for ICU care Aug. 6 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPVHg5LWs0b0xQY1lRQmxuZDREZ1p3WGtqR0d2WDJwMTViTVRXeUpLWDFaVGtEQVdsZkh0TE9ESUk0MmtXdEwxXy1xeWVzWXl0M21yOGNYakpGQnF0UzItNnlUWkJlTWdMcWNXTWdXSDM4OTJmX3RIWWhZZHVfeVRvM2tKbUFSTFhNdFRhbn…

Google News ue, 16 Jun 2026

Insider Purchase: Chief Financial Officer of $CTSO Buys 100,000 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNNEJQS2k3Q1djQ1ctajMtUy1mbk9STG5xWnJwVzJqX2FWLVZCN3hZUUlWOFdOVjhsUW1FaktwZzZzaWItekxsa29WM3VsQ29rZEZsc1lQQUh0ZEV4UXlVQkloU0lETzZ1bFU3cDBLRkxiakkzUEk4TWZsbk9DTHR5dVM1SURiM2dqS1NQWl…

Google News Fri, 31 Jul 2026

CTSO|Cytosorbents Corp|Price:0.358|Chg%:-0.003 - TradingKey

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE8td0xLTXF3UjNOLXVXWmhSaDUxd2gwNjY5cTF5b2o1UjRtNm5GeEM5QV9XNEJ1UHJRdWJ0VjcxdFBBU2cyT3dtRDRCaHpSMDRfMkxRWUdFWi0wWjNwZFZLWV9RaUtHQlZCM0tSZ2hR?oc=5" target="_blank">CTSO|Cytosorbents C…

Google News Fri, 12 Jun 2026

Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNUUwwVFhzcUZHZnhCYmh6NFl1VFNob3BpLXF2Y25IWml6MVczXzhkcmxEWDFhUHVjTGFfVjBGWUEwa1ViaG5RS0lVNzE0N1hzaFVJa2dmYlBXZi1WV3U1UzVJS2REa1ZuM3FXVENrbE5GRVEtX01STV9XMmFsMTZTc184NzV4TF83bFNGYk…

Google News Sat, 27 Jun 2026

Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQX1BpYWlJakpaOC16UlZ4SC1rcGhlTHVETzZCZnBlTWU3TGRxZ0dMMEQ1a2ZFTC1pMHNiOWpjb2owbkxMUGFxRUhSR3BfMGFzc2s0MnB5dnJMWmg0ZXd2anc5c1lERG92SzNCODc2VTVlOTFYWU9kQThhQ2gwQ1ZDdWV6NWdKaGVjaS12RE…

CTSO — Frequently Asked Questions

What is the current share price of CTSO?

As of 2026-08-05 17:25 PDT, CTSO trades at $0.38 on NASDAQ/NYSE. Its 52-week range is $0.35 to $1.20.

What is the P/E ratio of CTSO?

CTSO trades at a trailing price-to-earnings (P/E) ratio of -2.92.

What is the return on equity (ROE) of CTSO?

CTSO has a return on equity (ROE) of -138.88%. Its return on capital employed (ROCE) is -41.30%.

Is CTSO a good stock to buy?

This page provides a data-driven analysis of CTSO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

CTSO CTSO

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PR Newswire

CytoSorbents to discuss blood purification for ICU care Aug. 6 - Stock Titan

Insider Purchase: Chief Financial Officer of $CTSO Buys 100,000 Shares - Quiver Quantitative

CTSO|Cytosorbents Corp|Price:0.358|Chg%:-0.003 - TradingKey

Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st

Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow - Seeking Alpha

CTSO — Frequently Asked Questions

What is the current share price of CTSO?

What is the P/E ratio of CTSO?

What is the return on equity (ROE) of CTSO?

Is CTSO a good stock to buy?

Explore More